Kura Oncology, Inc. has entered into a Co-Promotion and Medical Affairs Agreement with Kyowa Kirin, Inc. to jointly promote Kura's product candidate, ziftomenib, in the United States. Ziftomenib, a potent and selective oral menin inhibitor, is aimed at treating acute myeloid leukemia and other hematologic malignancies. Under the agreement, Kyowa Kirin US will co-promote ziftomenib and meet certain sales requirements, while Kura will lead medical affairs activities. Both companies will share costs and collaborate on the health economics and outcomes research strategy. The agreement will remain effective until mutual cessation of commercialization or the expiration of relevant patent rights and regulatory exclusivity.